Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06985238 · ClinicalTrials.gov registry record · NA
Stratagen Quantitative Prostate MRI Platform Pilot Study
A NA study of Prostate Cancer, sponsored by Stratagen Bio.
- Recruiting
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT06985238: Recruiting NA study of Prostate Cancer, sponsored by Stratagen Bio.
NCT06985238 is a NA study of Prostate Cancer that is actively recruiting participants, run by Stratagen Bio. The registered enrollment target is 75 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06985238, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Stratagen Bio.
- RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters? Participants will: \- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Primary Outcome
All serious adverse events attributable to the Stratagen Quantitative Prostate MRI Platform will be reported.
Conditions Studied
Interventions
- DEVICE MRI
Study Locations (2)
New York
- Urology Clinic at Sawgrass - Rochester
Virginia
- Virginia Urology - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2026-10-31 |
| Phase | NA |
What NCT06985238 shows while recruiting
NCT06985238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT06985238 reports a single indexed study location in New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT06985238 about?
NCT06985238 is a clinical study titled "Stratagen Quantitative Prostate MRI Platform Pilot Study". The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quan...
What is the current status of trial NCT06985238?
This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2025-09-24. Estimated completion is 2026-10-31.
What conditions does trial NCT06985238 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06985238?
The interventions under investigation include: MRI (DEVICE).
Who is sponsoring clinical trial NCT06985238?
This trial is sponsored by Stratagen Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06985238 being conducted?
This trial has 2 study locations across New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06985238's enrollment target sits among peer trials
75 392nd of 735 higher than 341 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI